Maravai LifeSciences Holdings Inc. Class A Common Stock vs Warner Music Group Corp — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $977.37M), while Warner Music Group Corp trades at $29.07 (market cap $15.12B). The key difference: Warner Music Group Corp is far larger — about 15.5× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Warner Music Group Corp pays a 2.77% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Warner Music Group Corp for 97 Days on average.
| MRVI | WMG | |
|---|---|---|
Market Cap | $977.37M | $15.12B |
Volume | 2,742,564 | 1,727,670 |
Sector | Health | Media |
52-Week High | $9.00 | $34.72 |
52-Week Low | $2.83 | $23.65 |
Typical Hold Time | 0 Days | 97 Days |
Enterprise Value | $1.08B | $19.42B |
Dividend Yield | — | 2.77% |
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Warner Music Group (WMG) trades at $28.91, up 0.91% on the day, with a bullish technical signal from moving averages. The stock shows strong analyst support with a consensus price target of $39.50, representing significant upside. Recent earnings have beaten expectations in two of the last three quarters, with Q3 2026 results pending. The company maintains robust profitability with a 45.77% gross margin and 9.2% net margin, while revenue growth continues steadily from $6.71B in 2025 to a projected $7.3B in 2026.
WMG presents a compelling investment case with strong fundamentals, positive analyst sentiment, and strategic positioning in the evolving music industry, particularly through AI partnerships. However, risks include recent leadership changes, ongoing copyright litigation, and valuation metrics that appear elevated relative to historical norms. The stock's current price near recent highs suggests limited near-term upside without further positive catalysts.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →Warner Music Group is the third largest of the three major global record labels, with Vivendi's Universal Music in first and Sony Music in second. Warner's larger segment, recorded music, consists of iconic labels like Atlantic Records, Warner Records, and Parlophone Records and popular artists such as Ed Sheeran, Cardi B, Dua Lipa, and Blake Shelton. Warner Chappell, the firm's publishing arm, is the home to over 65,000 composers and songwriters with over a million copyrights represented. Warner is controlled by Access Industries, which owns an 84% economic interest and 99% of voting rights.
Read more on WMG →